Skip to main content
SpringerLink
Log in

Radionuclide Imaging of Head and Neck Paragangliomas

  • Chapter
  • First Online:
Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

Part of the book series: Contemporary Endocrinology ((COE))

  • 1172 Accesses

Abstract

Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors belonging to the family of pheochromocytoma/paraganglioma neoplasms. These tumors are specifically associated with the parasympathetic nervous system and therefore behave differently from those associated with the sympathetic nervous system (i.e., chromaffin tumors). This chapter will particularly emphasize current and emerging knowledge of imaging options on these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94:1541–7. doi:jc.2008-2419 [pii] 10.1210/jc.2008-2419.

    Article  CAS  PubMed  Google Scholar 

  2. Sykes JM, Ossoff RH. Paragangliomas of the head and neck. Otolaryngol Clin North Am. 1986;19:755–67.

    CAS  PubMed  Google Scholar 

  3. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metabol. 2001;86:5210–6.

    Article  CAS  Google Scholar 

  4. Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002;94:730–7.

    Article  PubMed  Google Scholar 

  5. Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf). 2013;78:898–906. doi:10.1111/cen.12074.

    Article  CAS  Google Scholar 

  6. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44(5):328–33.

    Google Scholar 

  7. Langerman A, Athavale SM, Rangarajan SV, Sinard RJ, Netterville JL. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg. 2012;138:341–5. doi:10.1001/archoto.2012.37.

    Article  PubMed  Google Scholar 

  8. le Douarin N, Kalcheim C. The neural crest. 2nd ed. Cambridge: Cambridge University Press; 1999.

    Book  Google Scholar 

  9. Unsicker K, Huber K, Schober A, Kalcheim C. Resolved and open issues in chromaffin cell development. Mech Dev. 2013;130:324–9. doi:10.1016/j.mod.2012.11.004.

    Article  CAS  PubMed  Google Scholar 

  10. Platero-Luengo A, Gonzalez-Granero S, Duran R, Diaz-Castro B, Piruat JI, Garcia-Verdugo JM, et al. An O2-sensitive glomus cell-stem cell synapse induces carotid body growth in chronic hypoxia. Cell. 2014;156:291–303. doi:10.1016/j.cell.2013.12.013.

    Article  CAS  PubMed  Google Scholar 

  11. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739–49. doi:10.1016/j.ejca.2011.07.016.

    Article  CAS  PubMed  Google Scholar 

  12. van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95:209–14. doi:10.1210/jc.2009-1632.

    Article  PubMed  Google Scholar 

  13. van Duinen N, Corssmit EP, de Jong WH, Brookman D, Kema IP, Romijn JA. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. Eur J Endocrinol. 2013;169:377–82. doi:10.1530/EJE-13-0529.

    Article  PubMed  Google Scholar 

  14. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42. doi:10.1210/jc.2014-1498.

    Article  CAS  PubMed  Google Scholar 

  15. Johnson MH. Head and neck vascular anatomy. Neuroimaging Clin N Am. 1998;8:119–41.

    CAS  PubMed  Google Scholar 

  16. van den Berg R, Schepers A, de Bruine FT, Liauw L, Mertens BJ, van der Mey AG, et al. The value of MR angiography techniques in the detection of head and neck paragangliomas. Eur J Radiol. 2004;52:240–5. doi:10.1016/j.ejrad.2003.12.002.

    Article  PubMed  Google Scholar 

  17. Neves F, Huwart L, Jourdan G, Reizine D, Herman P, Vicaut E, et al. Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol. 2008;29:883–9. doi:10.3174/ajnr.A0948.

    Article  CAS  PubMed  Google Scholar 

  18. van den Berg R. Imaging and management of head and neck paragangliomas. Eur Radiol. 2005;15:1310–8. doi:10.1007/s00330-005-2743-8.

    Article  PubMed  Google Scholar 

  19. Arnold SM, Strecker R, Scheffler K, Spreer J, Schipper J, Neumann HP, et al. Dynamic contrast enhancement of paragangliomas of the head and neck: evaluation with time-resolved 2D MR projection angiography. Eur Radiol. 2003;13:1608–11. doi:10.1007/s00330-002-1717-3.

    Article  PubMed  Google Scholar 

  20. Dong Y, Liu Q. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T. J Comput Assist Tomogr. 2012;36:361–6. doi:10.1097/RCT.0b013e31825975f8.

    Article  PubMed  Google Scholar 

  21. Bustillo A, Telischi F, Weed D, Civantos F, Angeli S, Serafini A, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114:434–40.

    Article  CAS  PubMed  Google Scholar 

  22. Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44:1767–74.

    PubMed  Google Scholar 

  23. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232–7.

    Article  PubMed  Google Scholar 

  24. Muros MA, Llamas-Elvira JM, Rodriguez A, Ramirez A, Gomez M, Arraez MA, et al. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998;19:735–42.

    Article  CAS  PubMed  Google Scholar 

  25. Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2002;29:1571–80.

    Article  CAS  PubMed  Google Scholar 

  26. Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg. 2000;122:358–62.

    CAS  PubMed  Google Scholar 

  27. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013;98:E162–73. doi:10.1210/jc.2012-2975.

    Article  CAS  PubMed  Google Scholar 

  28. Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [(1)(1)(1)In]pentetreotide-SPECT and [(1)F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf). 2011;74:21–9. doi:10.1111/j.1365-2265.2010.03893.x.

    Article  CAS  Google Scholar 

  29. Gabriel S, Blanchet EM, Sebag F, Chen CC, Fakhry N, Deveze A, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf). 2013;79:170–7. doi:10.1111/cen.12126.

    Article  CAS  Google Scholar 

  30. King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779–85. doi:10.1210/jc.2011-0333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Miederer M, Fottner C, Rossmann H, Helisch A, Papaspyrou K, Bartsch O, et al. High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [18F]fluorodihydroxyphenylalanine PET. Eur J Nucl Med Mol Imaging. 2013;40:889–96. doi:10.1007/s00259-013-2346-6.

    Article  CAS  PubMed  Google Scholar 

  32. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metabol. 2009;94:4757–67.

    Article  CAS  Google Scholar 

  33. Naji M, Al-Nahhas A. (68)Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:61–7. doi:10.1007/s00259-011-1990-y.

  34. Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13:769–75. doi:10.1007/s11307-010-0396-8.

    Article  PubMed  Google Scholar 

  35. Sharma P, Thakar A, Suman Kc S, Dhull VS, Singh H, Naswa N, et al. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med. 2013;54:841–7. doi:10.2967/jnumed.112.115485.

    Article  CAS  PubMed  Google Scholar 

  36. Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42:33–41. doi:10.1007/s00259-014-2892-6.

    Article  PubMed  Google Scholar 

  37. Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET/CT imaging in patients with multiple endocrine neoplasia syndromes. Clin Nucl Med. 2015;40:e351–6. doi:10.1097/RLU.0000000000000775.

    Article  PubMed  Google Scholar 

  38. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16. doi:10.1148/rg.352140164.

    Article  PubMed  Google Scholar 

  39. Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40:1800–8. doi:10.1007/s00259-013-2548-y.

    Article  CAS  PubMed  Google Scholar 

  40. Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888–95. doi:10.1158/1078-0432.CCR-14-2751.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Janssen I, Chen CC, Millo CM, Ling A, Taïeb D, Lin FI, et al. PET/CT comparing Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016; 43(10):1784–91.

    Google Scholar 

  42. Hofman MS, Hicks RJ. Moving beyond “Lumpology”: PET/CT imaging of pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3815–7. doi:10.1158/1078-0432.CCR-15-1073.

    Article  CAS  PubMed  Google Scholar 

  43. Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Prospective comparison of Ga-DOTATATE and F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3268-2.

    Google Scholar 

  44. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Piccini V, Rapizzi E, Bacca A, Di Trapani G, Pulli R, Giache V, et al. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer. 2012;19:149–55. doi:10.1530/ERC-11-0369.

    Article  CAS  PubMed  Google Scholar 

  46. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69:3650–6. doi:10.1158/0008-5472.CAN-08-4057.

    Article  CAS  PubMed  Google Scholar 

  47. Kunst HP, Rutten MH, de Monnink JP, Hoefsloot LH, Timmers HJ, Marres HA, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17:247–54.

    Article  CAS  PubMed  Google Scholar 

  48. Baysal BE. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim Biophys Acta. 1827;2013:573–7. doi:10.1016/j.bbabio.2012.12.005.

    Google Scholar 

  49. Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol. 2014;170:1–12. doi:10.1530/EJE-13-0623.

    Article  CAS  PubMed  Google Scholar 

  50. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16:79–88. doi:10.1038/sj.ejhg.5201904.

    Article  CAS  PubMed  Google Scholar 

  51. Blanchet EM, Gabriel S, Martucci V, Fakhry N, Chen CC, Deveze A, et al. (18) F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. Eur J Clin Invest. 2014;44:325–32. doi:10.1111/eci.12239.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262–9.

    Article  PubMed  Google Scholar 

  53. Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, et al. A comparison of the performance of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1266–70. doi:10.1007/s00259-012-2119-7.

    Article  CAS  PubMed  Google Scholar 

  54. Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME, et al. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. J Clin Oncol. 2016;34 (suppl 4S; abstr 194).

    Google Scholar 

  55. Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23. doi:10.1007/s00259-012-2309-3.

    Article  CAS  PubMed  Google Scholar 

  56. Cosetti M, Linstrom C, Alexiades G, Tessema B, Parisier S. Glomus tumors in patients of advanced age: a conservative approach. Laryngoscope. 2008;118:270–4. doi:10.1097/MLG.0b013e318158194b.

    Article  PubMed  Google Scholar 

  57. Fisch U, Mattox D. Microsurgery of the skull base. Stuttgart/New York: Georg Thieme Verlag; 1988. p. 148–281.

    Google Scholar 

  58. Fisch U. Infratemporal fossa approach to tumours of the temporal bone and base of the skull. J Laryngol Otol. 1978;92:949–67.

    Article  CAS  PubMed  Google Scholar 

  59. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998;124:1133–40.

    Article  CAS  PubMed  Google Scholar 

  60. Shamblin WR, ReMine WH, Sheps SG, Harrison Jr EG. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg. 1971;122:732–9.

    Article  CAS  PubMed  Google Scholar 

  61. Taïeb D, Hicks RJ, Pacak K. Radiopharmaceuticals in paraganglioma imaging: too many members on board? Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3213-4.

  62. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700–8. doi:10.1093/jnci/djs188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23:739–52. doi:10.1016/j.ccr.2013.04.018.

    Article  CAS  PubMed  Google Scholar 

  64. Lendvai N, Pawlosky R, Bullova P, Eisenhofer G, Patocs A, Veech RL, et al. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. Endocrinology. 2014;155:27–32. doi:10.1210/en.2013-1549.

    Article  PubMed  Google Scholar 

  65. Imperiale A, Moussallieh FM, Roche P, Battini S, Cicek AE, Sebag F, et al. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia. 2015;17:55–65. doi:10.1016/j.neo.2014.10.010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Imperiale A, Moussallieh FM, Sebag F, Brunaud L, Barlier A, Elbayed K, et al. A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas. PLoS One. 2013;8:e80539. doi:10.1371/journal.pone.0080539.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Lussey-Lepoutre C, Bellucci A, Morin A, Buffet A, Amar L, Janin M, et al. In vivo detection of succinate by magnetic resonance spectroscopy as a hallmark of SDHx mutations in paraganglioma. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-1576.

    PubMed  Google Scholar 

  68. Varoquaux A, le Fur Y, Imperiale A, Reyre A, Montava M, Fakhry N, et al. Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocr Relat Cancer. 2015;22:M1–8. doi:10.1530/ERC-15-0246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Heesterman BL, Bayley JP, Tops CM, Hes FJ, van Brussel BT, Corssmit EP, et al. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet. 2013;21:469–70. doi:10.1038/ejhg.2012.203.

    Article  CAS  PubMed  Google Scholar 

  70. Hensen EF, Jansen JC, Siemers MD, Oosterwijk JC, Vriends AH, Corssmit EP, et al. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Eur J Hum Genet. 2010;18:62–6. doi:10.1038/ejhg.2009.112.

    Article  PubMed  Google Scholar 

  71. Hes FJ, Weiss MM, Woortman SA, de Miranda NF, van Bunderen PA, Bonsing BA, et al. Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Med Genet. 2010;11:92. doi:10.1186/1471-2350-11-92.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Lepoutre-Lussey C, Caramella C, Bidault F, Deandreis D, Berdelou A, Al Ghuzlan A, et al. Screening in asymptomatic SDHx mutation carriers: added value of (1)(8)F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging. 2015;42:868–76. doi:10.1007/s00259-015-3003-z.

    Article  CAS  PubMed  Google Scholar 

  73. Holt A, Van Gestel D, Arends MP, Korevaar EW, Schuring D, Kunze-Busch MC, et al. Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study. Radiat Oncol. 2013;8:26. doi:10.1186/1748-717X-8-26.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Lim CM, Clump DA, Heron DE, Ferris RL. Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors. Oral Oncol. 2013;49:401–6. doi:10.1016/j.oraloncology.2012.12.009.

    Article  PubMed  Google Scholar 

  75. Liscak R, Simonova G, Vymazal J, Janouskova L, Vladyka V. Gamma knife radiosurgery of meningiomas in the cavernous sinus region. Acta Neurochir (Wien). 1999;141:473–80.

    Article  CAS  Google Scholar 

  76. Bianchi LC, Marchetti M, Brait L, Bergantin A, Milanesi I, Broggi G, et al. Paragangliomas of head and neck: a treatment option with CyberKnife radiosurgery. Neurol Sci. 2009;30:479–85. doi:10.1007/s10072-009-0138-3.

    Article  PubMed  Google Scholar 

  77. Gerszten PC, Ozhasoglu C, Burton SA, Vogel WJ, Atkins BA, Kalnicki S, et al. CyberKnife frameless single-fraction stereotactic radiosurgery for benign tumors of the spine. Neurosurg Focus. 2003;14:e16.

    Article  PubMed  Google Scholar 

  78. Golanov AV, Kapitanov DN, Pronin IN, Shelesko EV, Zolotova SV, Shchurova IN, et al. First experience of CyberKnife stereotactic radiotherapy for glomus jugulare tumors. Zh Vopr Neirokhir Im N N Burdenko. 2012;76:30–6; discussion 6.

    CAS  PubMed  Google Scholar 

  79. Lim M, Bower R, Nangiana JS, Adler JR, Chang SD. Radiosurgery for glomus jugulare tumors. Technol Cancer Res Treat. 2007;6:419–23.

    Article  PubMed  Google Scholar 

  80. Wegner RE, Rodriguez KD, Heron DE, Hirsch BE, Ferris RL, Burton SA. Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. Radiother Oncol. 2010;97:395–8. doi:10.1016/j.radonc.2010.09.004.

    Article  PubMed  Google Scholar 

  81. Henzel M, Hamm K, Gross MW, Surber G, Kleinert G, Failing T, et al. Fractionated stereotactic radiotherapy of glomus jugulare tumors. Local control, toxicity, symptomatology, and quality of life. Strahlenther Onkol. 2007;183:557–62. doi:10.1007/s00066-007-1701-6.

    Article  PubMed  Google Scholar 

  82. Poznanovic SA, Cass SP, Kavanagh BD. Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg. 2006;134:437–42. doi:10.1016/j.otohns.2005.10.040.

    Article  PubMed  Google Scholar 

  83. Zovato S, Kumanova A, Dematte S, Sansovini M, Bodei L, Di Sarra D, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44:411–4. doi:10.1055/s-0032-1311637.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France

    David Taïeb MD, PhD

  2. Department of Medical Imaging, Conception Hospital, Aix-Marseille University, 13005, Marseille, France

    Arthur Varoquaux MD, PhD

  3. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA

    Ingo Janssen MD & Karel Pacak MD, PhD, DSc, FACE

Authors
  1. David Taïeb MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arthur Varoquaux MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingo Janssen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karel Pacak MD, PhD, DSc, FACE
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Taïeb MD, PhD .

Editor information

Editors and Affiliations

  1. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver NICHD, NIH, Bethesda, Maryland, USA

    Karel Pacak

  2. Department of Nuclear Medicine, Aix-Marseille University, Marseille, France

    David Taïeb

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Taïeb, D., Varoquaux, A., Janssen, I., Pacak, K. (2017). Radionuclide Imaging of Head and Neck Paragangliomas. In: Pacak, K., Taïeb, D. (eds) Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-46038-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46038-3_13

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-46036-9

  • Online ISBN: 978-3-319-46038-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation